ImmunityBio Pipeline

* Investigator-sponsored studies

Anktiva® (N-803) is an interleukin-15 superagonist fusion protein that is designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells and (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Both agents are in late-stage clinical development by ImmunityBio, which has exclusive, worldwide rights to the agents. Pembrolizumab, sold under the brand KEYTRUDA®, is an FDA-approved immune checkpoint inhibitor marketed by Merck.
QUILT stands for QUantum Integrative Lifelong Trial.